Wedbush restated their neutral rating on shares of Sangamo BioSciences, Inc. (NASDAQ:SGMO) in a research note issued to investors on Wednesday. The brokerage currently has a $4.00 price target on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the stock. Piper Jaffray Companies cut shares of Sangamo BioSciences from an overweight rating to a neutral rating and reduced their target price for the stock from $9.00 to $5.00 in a report on Wednesday, October 19th. Zacks Investment Research raised shares of Sangamo BioSciences from a sell rating to a hold rating in a report on Thursday, October 20th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $7.75.
Sangamo BioSciences (NASDAQ:SGMO) opened at 3.85 on Wednesday. The company’s market cap is $271.90 million. The company has a 50-day moving average of $3.60 and a 200 day moving average of $4.06. Sangamo BioSciences has a one year low of $2.65 and a one year high of $7.60.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. Quantitative Systematic Strategies LLC purchased a new position in shares of Sangamo BioSciences during the second quarter valued at about $163,000. Russell Investments Group Ltd. purchased a new position in shares of Sangamo BioSciences during the fourth quarter valued at about $179,000. Bourgeon Capital Management LLC raised its position in shares of Sangamo BioSciences by 12.6% in the second quarter. Bourgeon Capital Management LLC now owns 49,000 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 5,500 shares during the last quarter. Sicart Associates LLC purchased a new position in shares of Sangamo BioSciences during the fourth quarter valued at about $311,000. Finally, Wedbush Securities Inc. raised its position in shares of Sangamo BioSciences by 30.0% in the third quarter. Wedbush Securities Inc. now owns 80,020 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 18,450 shares during the last quarter. 62.30% of the stock is owned by institutional investors.
Sangamo BioSciences Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/sangamo-biosciences-inc-sgmo-earns-neutral-rating-from-wedbush/1657560.html
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.